Stockscreener 앱 받기
18.03
1.26%
-0.23
시간 외 거래:
18.24
0.21
+1.16%
전일 마감가:
$18.26
열려 있는:
$17.74
하루 거래량:
1.44M
Relative Volume:
0.38
시가총액:
$13.39B
수익:
$220.00K
순이익/손실:
$-746.08M
주가수익비율:
-17.90
EPS:
-1.0074
순현금흐름:
$-211.81M
1주 성능:
-0.83%
1개월 성능:
-17.10%
6개월 성능:
-20.75%
1년 성능:
-7.30%
1일 변동 폭
$17.74
$18.57
1주일 범위
$17.74
$19.40
52주 변동 폭
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.03 | 13.59B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Is Summit Therapeutics Inc. stock a safe haven assetForecast Cut & Short-Term High Return Ideas - Fundação Cultural do Pará
What MACD and RSI say about Summit Therapeutics Inc.Weekly Trend Summary & Safe Capital Growth Plans - newser.com
Is Summit Therapeutics Inc. building a consolidation baseMarket Risk Report & Low Volatility Stock Recommendations - newser.com
Has Summit Therapeutics Inc. found a price floorPortfolio Risk Summary & Risk Controlled Daily Trade Plans - newser.com
Analyzing Summit Therapeutics Inc. with risk reward ratio chartsWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Can Summit Therapeutics Inc. hit a new high this monthInsider Selling & Weekly Return Optimization Plans - newser.com
Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial - Yahoo Finance
Responsive Playbooks and the SMMT Inflection - news.stocktradersdaily.com
Summit and Akeso ivonescimab’s shows significant OS benefit - The Pharma Letter
Clear Street Remains a Buy on Summit Therapeutics (SMMT) - The Globe and Mail
Insiders Are Buying These 3 Stocks Hand Over Fist - AOL.com
Summit Therapeutics Reports Positive Phase III Trial Results - MSN
What institutional flow reveals about Summit Therapeutics Inc.2025 Market Outlook & Weekly High Momentum Picks - newser.com
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China - Placera.se
Summit Therapeutics Says Ivonescimab, Chemotherapy Combination Shows Benefit in Treating Lung Cancer - MarketScreener
Summit Therapeutics Inc Reports Positive Phase III Trial Results - TradingView
[8-K] Summit Therapeutics Inc. Reports Material Event | SMMT SEC FilingForm 8-K - Stock Titan
Summit (NASDAQ: SMMT): ivonescimab combo OS 16.8 vs 14.1 mo in EGFRm NSCLC - Stock Titan
Should you hold or exit Summit Therapeutics Inc. nowEarnings Overview Summary & Advanced Technical Signal Analysis - newser.com
Is Summit Therapeutics Inc. showing signs of accumulationJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Will Summit Therapeutics Inc. stock outperform growth indexesSwing Trade & Verified Short-Term Trading Plans - fcp.pa.gov.br
Applying sector rotation models to Summit Therapeutics Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
Transforming Lung Cancer Care Through Targeted Science and Patient-First InnovationSummit Therapeutics - Oncodaily
Summit Therapeutics to Present at Upcoming Investor ConferencesNovember 4, 2025 - BioSpace
Is Summit Therapeutics Inc. stock reversal real or fakeShare Buyback & Daily Oversold Bounce Ideas - newser.com
Summit Therapeutics Inc.Common Stock (Nasdaq:SMMT) Stock Quote - Markets Financial Content
Summit Therapeutics Earnings Notes - Trefis
Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed? - Yahoo Finance
News impact scoring models applied to Summit Therapeutics Inc.Trade Signal Summary & Daily Technical Forecast Reports - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress - Yahoo Finance
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
1.43%
0.07%
자본화:
|
볼륨(24시간):